Название продукции:(R)-2-methylpropane-2-sulfinamide

IUPAC Name:(R)-2-methylpropane-2-sulfinamide

CAS:196929-78-9
Молекулярная формула:C4H11NOS
Чистота:99%
Номер в каталоге:CM112195
Молекулярная масса:121.2

Упаковочная единица Доступно для заказа Цена ($) Количество
CM112195-200g in stock şǠ

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:196929-78-9
Молекулярная формула:C4H11NOS
Точка плавления:-
Smiles-код:CC([S@](N)=O)(C)C
Плотность:
Номер в каталоге:CM112195
Молекулярная масса:121.2
Точка кипения:
Номер Mdl:MFCD05861479
Хранение:Keep in a tight container and store at 2°C~8°C

Column Infos

Nitrogen Compounds
Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.
Repotrectinib
Repotrectinib receives approval for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) from the U.S. FDA on November 15, 2023. ROS1 gene is altered in about 1-2% of patients with NSCLC. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones.
Repotrectinib is a highly potent and differentiated small molecule TKI that binds inside the ATP pocket, and is active against both wild-type and resistant mutations, including solvent front and gatekeeper mutations. Repotrectinib is expected to enter the U.S. market in mid-December 2023.
Olutasidenib
Rigel announces publication of data on REZLIDHIA(Olutasidenib) in post-venetoclax patients with mutant IDH1 AML in Leukemia & Lymphoma.
REZLIDHIA (Olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1), in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.